ITRACONAZOLE | N020966 | JANSSEN PHARMACEUTICALS INC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 1 | Active | AbbVie | 12 | 2026-05-07 → 2026-09 | |
| Phase 1 | Active | Merck Sharp & Dohme LLC | 28 | 2026-03-06 → 2026-08-12 | |
| Phase 1 | Active | Astellas Pharma Global Development, Inc. | 54 | 2026-02-03 → 2027-05-02 | |
| Phase 1/2 | Active | Kura Oncology, Inc. | 263 | 2019-09-12 → 2028-10-16 | |
| Phase 1 | Not Yet Recruiting | Boehringer Ingelheim | 16 | 2026-09-01 → 2026-10-26 | |
| Phase 1 | Not Yet Recruiting | AbbVie | 20 | 2026-08-21 → 2027-02 | |
| Phase 1 | Not Yet Recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 8 | 2026-08-01 → 2027-03-31 | |
| Phase 1 | Not Yet Recruiting | H. Lundbeck A/S | 46 | 2026-08-27 → 2026-11-06 | |
| Phase 1 | Not Yet Recruiting | Novartis Pharmaceuticals | 30 | 2026-08-27 → 2026-11-15 | |
| Phase 4 | Not Yet Recruiting | Pak Emirates Military Hospital | 60 | 2026-10-01 → 2027-03-01 |
Source: ClinicalTrials.gov. Trials matched by ingredient name; data refreshed each weekday and may lag the registry.
11 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Apr 27, 2009 | SUPPL -22 | View Letter (PDF) |
| Mar 10, 2009 | SUPPL -20 | View Letter (PDF) |
| Mar 10, 2009 | SUPPL -18 | View Letter (PDF) |
| Mar 10, 2009 | SUPPL -17 | View Letter (PDF) |
| Jul 21, 2004 | SUPPL -11 | View Letter (PDF) |
| Jul 17, 2002 | SUPPL -6 | View Letter (PDF) |
| Feb 28, 2002 | SUPPL -5 | View Letter (PDF) |
| Apr 17, 2001 | SUPPL -4 | View Letter (PDF) |
| Apr 17, 2001 | SUPPL -1 | View Letter (PDF) |
| Apr 17, 2001 | SUPPL -3 | View Letter (PDF) |
| Mar 30, 1999 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.